Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Five Prime Therapeutics, Inc.
South San Francisco, California, United States of Americafiveprime.com ↗
- Ownership
- Private
- Employees
- ~134
- Development stage
- Other
01
Overview
Phase 2 FIGHT trial showed bemarituzumab plus chemotherapy reduced risk of death by 42% versus chemotherapy alone in FGFR2b-positive, first-line advanced gastric or GEJ cancer patients. Final analysis showed median OS of 19.2 months versus 13.5 months (HR=0.77)[6]
- Therapeutic areas
- Oncology
- Modalities
- Antibodies
- Industry
- Biotech
02
Partnerships
Bristol-Myers SquibbZai Lab (Shanghai) Co., Ltd.Galaxy Biotech, LLCBioWa, Inc.Lonza Sales AGSeagen (Seattle Genetics)
Beyond the preview
Go deeper on Five Prime Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Five Prime Therapeutics, Inc..